All In Biotech

Drug Trial Radar · NCT04551248

Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.

Post-marketing Safety Evaluation of 10 or 13-valent Pneumococcal Conjugate Vaccine in Children and 23-valent Pneumococcal Polysaccharide Vaccine in Elderly Adults.

Last checked: Nov 19, 2026Latest source record: Sep 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

1,000,000

Planned (sponsor's estimate)

Start

Aug 1, 2021

Primary completion

Mar 31, 2022

Study completion Mar 31, 2022

Sponsor

Lead sponsor
Sungkyunkwan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Government-wide R&D Fund project for infectious disease research
First posted
Sep 16, 2020

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this observational study is to examine the risk of adverse events following vaccination with 10 or 13-valent pneumococcal conjugate vaccine (PCV10 or PCV13) among infants or children age \<59 months and 23-valent pneumococcal polysaccharide vaccine (PPSV23) among adults age 65 years and older.

Conditions

  • Pneumococcal Vaccine Adverse Reaction

Interventions

  • 10 or 13-valent pneumococcal conjugate vaccineBiological

    a four-dose series that is indicated for use at 2, 4, 6, and 12 to 15 months of age.

  • 23-valent pneumococcal polysaccharide vaccineBiological

    Single 0.5-mL dose administered intramuscularly or subcutaneously only.

  • Influenza vaccineBiological

    One dose of trivalent influenza vaccine in flu seasons.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative risk of adverse eventsTime frame: 2014-2018

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sungkyunkwan University

    Suwon, Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.